Folgen
Krishna C Bulusu
Krishna C Bulusu
Bestätigte E-Mail-Adresse bei astrazeneca.com
Titel
Zitiert von
Zitiert von
Jahr
DeepSynergy: predicting anti-cancer drug synergy with Deep Learning
K Preuer, RPI Lewis, S Hochreiter, A Bender, KC Bulusu, G Klambauer
Bioinformatics 34 (9), 1538-1546, 2018
4062018
Community assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen
MP Menden, D Wang, MJ Mason, B Szalai, KC Bulusu, Y Guan, T Yu, ...
Nature communications 10 (1), 2674, 2019
2702019
Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study
VA Papadimitrakopoulou, YL Wu, JY Han, MJ Ahn, SS Ramalingam, ...
Annals of Oncology 29, viii741, 2018
2472018
Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study
VA Papadimitrakopoulou, YL Wu, JY Han, MJ Ahn, SS Ramalingam, ...
Annals of Oncology 29, viii741, 2018
2472018
Modelling of compound combination effects and applications to efficacy and toxicity: state-of-the-art, challenges and perspectives
KC Bulusu, R Guha, DJ Mason, RPI Lewis, E Muratov, YK Motamedi, ...
Drug discovery today 21 (2), 225-238, 2016
1892016
Development of a novel azaspirane that targets the Janus kinase-signal transducer and activator of transcription (STAT) pathway in hepatocellular carcinoma in vitro and in vivo
CD Mohan, H Bharathkumar, KC Bulusu, V Pandey, S Rangappa, ...
Journal of Biological Chemistry 289 (49), 34296-34307, 2014
1622014
canSAR: updated cancer research and drug discovery knowledgebase
KC Bulusu, JE Tym, EA Coker, AC Schierz, B Al-Lazikani
Nucleic acids research 42 (D1), D1040-D1047, 2014
1002014
canSAR: an integrated cancer public translational research and drug discovery resource
MD Halling-Brown, KC Bulusu, M Patel, JE Tym, B Al-Lazikani
Nucleic acids research 40 (D1), D947-D956, 2012
872012
Early clearance of plasma EGFR mutations as a predictor of response to osimertinib and comparator EGFR-TKIs in the FLAURA trial.
C Zhou, F Imamura, Y Cheng, I Okamoto, BC Cho, MC Lin, M Majem, ...
Journal of Clinical Oncology 37 (15_suppl), 9020-9020, 2019
622019
Novel adamantanyl-based thiadiazolyl pyrazoles targeting EGFR in triple-negative breast cancer
A Sebastian, V Pandey, CD Mohan, YT Chia, S Rangappa, J Mathai, ...
ACS omega 1 (6), 1412-1424, 2016
452016
Microwave-assisted synthesis, characterization and cytotoxic studies of novel estrogen receptor α ligands towards human breast cancer cells
H Bharathkumar, CD Mohan, H Ananda, JE Fuchs, F Li, S Rangappa, ...
Bioorganic & medicinal chemistry letters 25 (8), 1804-1807, 2015
452015
Knowledge graph-based recommendation framework identifies drivers of resistance in EGFR mutant non-small cell lung cancer
A Gogleva, D Polychronopoulos, M Pfeifer, V Poroshin, M Ughetto, ...
Nature communications 13 (1), 1667, 2022
412022
Orthologue chemical space and its influence on target prediction
LH Mervin, KC Bulusu, L Kalash, AM Afzal, F Svensson, MA Firth, I Barrett, ...
Bioinformatics 34 (1), 72-79, 2018
402018
Neighbours of cancer-related proteins have key influence on pathogenesis and could increase the drug target space for anticancer therapies
D Módos, KC Bulusu, D Fazekas, J Kubisch, J Brooks, I Marczell, ...
NPJ systems biology and applications 3 (1), 2, 2017
332017
A One Pot Synthesis of Novel Bioactive Tri-Substitute-Condensed-Imidazopyridines that Targets Snake Venom Phospholipase A2
NC Anilkumar, MS Sundaram, CD Mohan, S Rangappa, KC Bulusu, ...
PloS one 10 (7), e0131896, 2015
322015
A cancer pharmacogenomic screen powering crowd-sourced advancement of drug combination prediction
MP Menden, D Wang, Y Guan, MJ Mason, B Szalai, KC Bulusu, T Yu, ...
BioRxiv, 200451, 2017
282017
Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial
J Chmielecki, T Mok, YL Wu, JY Han, MJ Ahn, SS Ramalingam, T John, ...
Nature communications 14 (1), 1071, 2023
242023
Identification of a molecularly-defined subset of breast and ovarian cancer models that respond to WEE1 or ATR inhibition, overcoming PARP inhibitor resistance
V Serra, AT Wang, M Castroviejo-Bermejo, UM Polanska, M Palafox, ...
Clinical Cancer Research 28 (20), 4536-4550, 2022
162022
Community assessment of cancer drug combination screens identifies strategies for synergy prediction
MP Menden, D Wang, Y Guan, M Mason, B Szalai, KC Bulusu, T Yu, ...
bioRxiv 200451, 1-32, 2017
122017
Basappa; Sethi, G.; Rangappa, KS
CD Mohan, H Bharathkumar, KC Bulusu, V Pandey
J. Biol. Chem 289, 34296, 2014
122014
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20